Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab)

Bone Marrow Transplantation volume 48, pages 186–190 (2013)Cite this article

Subjects

Abstract

Antithymocyte globulin (ATG)-based immunosuppression remains the standard immunosuppressive therapy (IST) for aplastic anemia (AA) patients lacking a sibling donor; however, treatment failures are relatively frequent, including about one-quarter to one-third of patients who do not show any response to initial IST, and about half of the initial responders who may experience subsequent relapses or require continuous maintenance IST. For these patients, there is the option of further IST, which may include additional courses of ATG-based IST, or attempts with alternative IST regimens. Alemtuzumab is a monoclonal anti-CD52 Ab, which has been recently investigated as novel IS agent for the treatment of AA patients. Recent data from different groups have clearly demonstrated the biological efficacy of Alemtuzumab in AA patients, ruling out the initial concerns about possible unacceptable infectious risks secondary to its extremely powerful lympholytic effect. Preliminary data demonstrate a remarkable efficacy, especially in the context of relapsed and, to less extent, refractory patients, whereas data in naïve patients are still limited. On the basis of these results, Alemtuzumab-based immunosuppression is a worthy option for AA and other marrow failure patients requiring a second-line IST. Here we describe a consensus regimen that the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party suggests for AA patients failing initial IST who are not indicated for SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Young NS . Acquired aplastic anemia. In: Young NS (ed.). Bone Marrow Failure Syndromes. WB Saunders: Philadelphia, 2000, pp 1–46.

    Google Scholar 

  2. Young NS, Maciejewski J . The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365–1372.

    Article  CAS  PubMed  Google Scholar 

  3. Young NS, Calado RT, Scheinberg P . Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509–2519.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS . In vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004; 364: 355–364.

    Article  CAS  PubMed  Google Scholar 

  5. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43–70.

    Article  CAS  PubMed  Google Scholar 

  6. Risitano AM . Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. Br J Haematol 2011; 152: 127–140.

    Article  CAS  PubMed  Google Scholar 

  7. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med 1991; 324: 1297–1304.

    Article  CAS  PubMed  Google Scholar 

  8. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101: 1236–1242.

    Article  CAS  PubMed  Google Scholar 

  9. Marsh J . Making therapeutic decisions in adults with aplastic anemia. Hematol Am Soc Hematol Educ Program 2006, 78–85.

  10. Bacigalupo A . Aplastic anemia: pathogenesis and treatment. Hematol Am Soc Hematol Educ Program 2007, 23–28.

  11. Rosenfeld SJ, Kimball J, Vining D, Young NS . Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85: 3058–3065.

    CAS  PubMed  Google Scholar 

  12. Rosenfeld S, Follmann D, Nunez O, Young NS . Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. J Am Med Assoc 2003; 289: 1130–1135.

    Article  CAS  Google Scholar 

  13. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A et al. Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 92: 11–18.

    Article  CAS  PubMed  Google Scholar 

  14. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95: 1931–1934.

    CAS  PubMed  Google Scholar 

  15. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110: 1756–1761.

    Article  CAS  PubMed  Google Scholar 

  16. Scheinberg P, Nunez O, Weinstein BP, Scheinberg P, Biancotto A, Wu CO et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430–438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Marsh J, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012; 119: 5391–5396.

    Article  CAS  PubMed  Google Scholar 

  18. Scheinberg P, Wu CO, Nunez O, Young NS . Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009; 144: 206–216.

    Article  CAS  PubMed  Google Scholar 

  19. Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009; 94: 348–354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U et al. A randomized controlled study in newly-diagnosed severe aplastic anemia patients receiving antithymocyte globulin, ciclosporin, with or without G-CSF. Blood 2011; 117: 4434–4441.

    Article  CAS  PubMed  Google Scholar 

  21. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS . Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129–3135.

    Article  CAS  PubMed  Google Scholar 

  22. Tichelli A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Wodnar-Filipowicz A et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998; 100: 393–400.

    Article  CAS  PubMed  Google Scholar 

  23. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999; 107: 330–334.

    Article  CAS  PubMed  Google Scholar 

  24. Scheinberg P, Nunez O, Young NS . Re-treatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006; 133: 622–627.

    Article  CAS  PubMed  Google Scholar 

  25. Schrezenmeier H, Marin P, Raghavachar A, McCann S, Hows J, Gluckman E et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993; 85: 371–377.

    Article  CAS  PubMed  Google Scholar 

  26. Scheinberg P, Nunez O, Wu C, Young NS . Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006; 133: 606–611.

    Article  CAS  PubMed  Google Scholar 

  27. Brodsky RA, Sensenbrenner LL, Jones RJ . Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996; 87: 491–494.

    CAS  PubMed  Google Scholar 

  28. Tisdale JF, Dunn DE, Geller N, Plante M, Nunez O, Dunbar CE et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000; 356: 1554–1559.

    Article  CAS  PubMed  Google Scholar 

  29. Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS . Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood 2002; 100: 4668–4670.

    Article  CAS  PubMed  Google Scholar 

  30. Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010; 115: 2136–2141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dumont FJ . Alemtuzumab (Millennium/ILEX). Curr Opin Invest Drugs 2001; 2: 139–160.

    CAS  Google Scholar 

  32. Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica 2009; 94: 1407–1414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801.

    Article  Google Scholar 

  34. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo Campath-1H prevents graft-versus-host disease following non myeloablative stem cell transplantation. Blood 2000; 96: 2419–2425.

    CAS  PubMed  Google Scholar 

  35. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    Article  CAS  PubMed  Google Scholar 

  36. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351–2357.

    Article  CAS  PubMed  Google Scholar 

  37. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantation: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404–406.

    Article  CAS  PubMed  Google Scholar 

  38. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulins responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous route of administration. Blood 2004; 104: 948–955.

    Article  CAS  PubMed  Google Scholar 

  39. Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S et al. Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148: 791–796.

    Article  CAS  PubMed  Google Scholar 

  40. Willis F, Marsh JCW, Bevan DH, Killick SB, Lucas G, Griffiths R et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114: 891–898.

    Article  CAS  PubMed  Google Scholar 

  41. Risitano AM, Serio B, Selleri C, Rotoli B . Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. Ann Hematol 2009; 88: 1261–1262.

    Article  PubMed  Google Scholar 

  42. Marotta S, Selleri C, Serio B, Raia M, Del Vecchio L, De Palma R et al. Long-term follow up of a pilot study with alemtuzumab and low-dose cyclosporine A for aplastic anemia and single-lineage marrow failures. Bone Marrow Transplant 2012; 47 (Suppl 1): 223.

    Google Scholar 

  43. Gibbs SD, Westerman DA, McCormack C, Seymour JF, Miles Prince H . Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005; 130: 87–91.

    Article  CAS  PubMed  Google Scholar 

  44. Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R et al. Emergence of CD52−, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995; 86: 1487–1492.

    CAS  PubMed  Google Scholar 

  45. Taylor VC, Sims M, Brett S, Field MC . Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism. Biochem J 1997; 322: 919–925.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Rawstron AC, Rollinson SJ, Richards S, Short MA, English A, Morgan GJ et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999; 107: 148–153.

    Article  CAS  PubMed  Google Scholar 

  47. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS . Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012; 119: 345–354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Scheinberg P, Fischer SH, Li L, Wu CO, Sloand EM, Cohen JI et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109: 3219–3224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kim H, Min YJ, Baek JH, Shin SJ, Lee EH, Noh EK et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009; 33: 222–231.

    Article  CAS  PubMed  Google Scholar 

  50. Gómez-Almaguer D, Jaime-Pérez JC, Garza-Rodríguez V, Chapa-Rodríguez A, Tarín-Arzaga L, Herrera-Garza JL et al. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol 2010; 89: 299–303.

    Article  PubMed  Google Scholar 

  51. Sawada K, Fujishima N, Hirokawa M . Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 2008; 142: 505–514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Au WY, Lam CC, Chim CS, Pang AW, Kwong YL . Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 2005; 29: 1213–1215.

    Article  CAS  PubMed  Google Scholar 

  53. Ru X, Liebman HA . Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003; 123: 278–281.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Medical Biotechnologies, Hematology, Federico II University of Naples, Naples, Italy

    A M Risitano

  2. Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University of Ulm, Ulm, Germany

    H Schrezenmeier

Authors
  1. A M Risitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Schrezenmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A M Risitano.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Risitano, A., Schrezenmeier, H. Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab). Bone Marrow Transplant 48, 186–190 (2013). https://doi.org/10.1038/bmt.2012.245

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.245

Keywords

This article is cited by

Search

Advanced search

Quick links